About Empaa-M XR Tablet 25mg/1000mg
Empagliflozin and Metformin XR tablet for blood sugar control in type 2 diabetes.
Empaa-M XR Tablet 25mg/1000mg Uses
- Type 2 diabetes management relies on this combination to control high blood sugar in adults
- Diet and exercise plans often need this add on medicine when metformin alone is not enough
- Heart related complication risk reduction is a key reason doctors prescribe it for diabetic patients with existing heart disease
- Kidney strain in people with type 2 diabetes and kidney disease can be reduced with this combination
- Overall glucose control as part of a broader combination therapy plan is another common use
Empaa-M XR Tablet 25mg/1000mg Benefits
- Two proven diabetes medicines come together in one extended release tablet
- The kidneys remove excess sugar through urine with help from empagliflozin
- Liver sugar release drops with metformin's action, supporting steadier blood sugar
- Modest weight loss is possible compared to some other diabetes medicines
- Once daily dosing from the extended release formula supports better routine adherence
- Cardiovascular risk reduction is documented in patients with type 2 diabetes and heart disease
What Experts Say
Empagliflozin belongs to a class of medicines called SGLT2 inhibitors, which work by blocking sugar reabsorption in the kidneys so excess glucose leaves the body through urine. Metformin, the other component, lowers blood sugar mainly by reducing glucose production in the liver and improving how the body responds to insulin. Together they target diabetes from two different angles.
Large cardiovascular outcome trials show empagliflozin can lower the risk of heart failure hospitalization and cardiovascular death in people with type 2 diabetes who already have heart disease. Metformin remains the first line diabetes treatment worldwide due to its strong safety record and low cost. This combination is often prescribed once metformin alone no longer controls blood sugar.
Extended release formulations like this one are designed to release the medicine slowly, which reduces stomach related side effects and allows once daily dosing. Regular kidney function monitoring is recommended during treatment since both components are affected by how well the kidneys work. Doctors typically start with a lower dose and adjust it gradually based on blood sugar response.
Drug Class
- SGLT2 inhibitor (Empagliflozin)
- Biguanide (Metformin)
- Antidiabetic combination therapy
Empaa-M XR Tablet 25mg/1000mg Uses in Urdu
- ٹائپ ٹو ذیابیطس میں بلڈ شوگر کو قابو میں رکھنے کے لیے استعمال ہوتی ہے
- جب اکیلی میٹفارمن سے شوگر کنٹرول نہ ہو تو اضافی علاج کے طور پر دی جاتی ہے
- ذیابیطس کے مریضوں میں دل کی بیماری کے خطرے کو کم کرنے میں مدد دیتی ہے
- گردوں پر پڑنے والے دباؤ کو کم کرنے میں معاون ثابت ہوتی ہے
- پیشاب کے ذریعے اضافی شوگر خارج کرنے میں مدد دیتی ہے
Empaa-M XR Tablet 25mg/1000mg formula
- Empagliflozin + Metformin Hydrochloride
How to use Empaa-M XR Tablet 25mg/1000mg?
- One tablet is usually taken once daily with the morning meal
- The tablet should be swallowed whole without crushing or chewing it
- A consistent daily timing helps maintain steady blood sugar control
- Meals should not be skipped after taking this medicine to avoid low blood sugar
- The prescribed dose should not be adjusted without medical advice
Drug Interactions
- Insulin and sulfonylureas: Combined use raises hypoglycemia risk and may need a dose adjustment
- Diuretics: Dehydration and low blood pressure risk increase when combined with empagliflozin
- Contrast dye for imaging: Metformin is usually paused around procedures using iodinated contrast due to kidney related lactic acidosis risk
- Alcohol: Heavy use raises the risk of lactic acidosis and low blood sugar
- Corticosteroids: Blood sugar levels may rise, reducing how well this medicine works
Risks and warnings
- Lactic acidosis: A rare but serious risk with metformin, more likely in people with kidney or liver problems; unusual muscle pain, breathing trouble or extreme tiredness need urgent medical attention
- Kidney function: Regular monitoring is required since both components depend on healthy kidney function
- Dehydration and low blood pressure: Empagliflozin increases urination and can cause dehydration, especially in hot weather or with low fluid intake
- Genital infections: Higher risk of yeast infections and urinary tract infections due to increased sugar in urine
- Diabetic ketoacidosis: A rare risk even with normal blood sugar levels; nausea, vomiting or unusual fatigue need prompt medical attention
- Surgery: A temporary pause before major surgery or contrast dye procedures is often advised by the treating doctor
- Pregnancy: Not recommended during pregnancy; alternative options are best discussed with the treating doctor
Empaa-M XR Tablet 25mg/1000mg Side Effects
- Nausea or stomach upset
- Diarrhea
- Metallic taste in the mouth
- Reduced appetite
- Increased urination
- Genital yeast infections
- Urinary tract infections
- Dizziness or lightheadedness
- Low blood sugar when combined with insulin or sulfonylureas
- Dehydration
- Rare risk of lactic acidosis
- Rare risk of diabetic ketoacidosis
Storage Conditions
- Store below 30 degrees Celsius in a dry place away from direct light
- Keep tablets in the original blister pack until the dose is due
- Keep out of reach of children
- Avoid storing in a bathroom cabinet due to humidity
- Discard any unused tablets after the printed expiry date
